DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Therapy Targeting the Interleukin-3 Receptor (IL3R) for Patients With Relapsed or Refractory and Elderly or Poor-Risk Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome With DTIL3 (IND# 11314): a Phase I/II Clinical Trial
Sponsor: University of Texas Southwestern Medical Center
A PHASE1/PHASE2 clinical study on Blastic Plasmacytoid Dendritic Cell Neoplasm and Leukemia, this trial is completed. The trial is conducted by University of Texas Southwestern Medical Center and has accumulated 9 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 4 earlier versions
-
May 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — May 2019 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
May 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Texas Southwestern Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .